Table 5

Effect of therapy with oral taxane (BMS-275183) after induction therapy with i.v. paclitaxel in mice bearing staged s.c. mammary 16/C carcinoma (experiment B)

Treatment (mg/kg/injection)Effect
Paclitaxel qd 10-14, i.v.BMS-275183, p.o.T-C (cures/totala)
q2d×11; d.21q4d×6; d.21
4514.3 (1/8)
3014.5 (2/8)
4520Toxic
451329.8 (2/8)b
3020Toxic
301326.3 (2/8)
2030Toxic
202030.3 (1/8)
201319.3
4545Toxic
453041.8 (1/8)c
452021.5
304535.3 (3/8)b
303033.3 (2/8)
302028.3
204518.3
203017.3
  • a Cures assessed on day 60 after tumor implant. T-C (in days): see footnote a of Table 4<$REFLINK> . There were eight mice/treatment group.

  • b Significantly different (P < 0.05) from paclitaxel optimum result.

  • c Significantly different (P < 0.01) from paclitaxel optimum result.